PCVX Q4 2022 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$87M

Net Income

-$78M

EPS (Diluted)

$-1.03

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$66M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$53M

Stockholders' Equity

$954M

Cash & Equivalents

$835M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$87M	-$30M	-190.1%
Net Income	-$78M	-$29M	-173.3%